ImmuPharma plc (LON:IMM – Get Free Report) shares traded down 15.3% during trading on Wednesday . The stock traded as low as GBX 4.60 ($0.06) and last traded at GBX 5 ($0.06). 57,070,488 shares traded hands during trading, an increase of 126% from the average session volume of 25,258,289 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Price Performance
The firm has a market capitalization of £23.49 million, a price-to-earnings ratio of -564.00 and a beta of 1.53. The firm’s 50-day simple moving average is GBX 2.06 and its 200 day simple moving average is GBX 1.83.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- How to Invest in Small Cap Stocks
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Stock Dividend Cuts Happen Are You Ready?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
